Coeptis Therapeutics Holdings Inc
Coeptis Therapeutics Holdings Inc is a biotechnology company focused on pharmaceuticals and medical research.
Business. Coeptis Therapeutics Holdings Inc (COEP.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As segment and geographic breakdowns are not specified, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Coeptis Therapeutics Holdings Inc (COEP.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As segment and geographic breakdowns are not specified, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.
Coeptis Therapeutics operates with a capital structure that includes $250,000 in long-term debt and $13,561,990 in total equity, resulting in a debt-to-equity ratio of 0.02. The company's liquidity position is characterized by a current ratio of 4.16, indicating strong short-term liquidity. However, the company has a negative net cash position after subtracting total debt, which is a key liquidity flag.
Profitability metrics show significant challenges, with a return on equity (ROE) of -87.87% and a return on assets (ROA) of -73.77%. These figures are well below the industry median for biotechnology firms, which typically report positive ROE and ROA in the range of 10-20% and 5-10%, respectively. The company reported a net loss of $11,917,020 and an operating loss of $12,884,460 in the latest period.
The company's revenue for the period was $1,363,050, with a gross profit of $1,182,420. There is no disclosed segment or geographic breakdown in the available data, so it is not possible to assess revenue concentration or geographic exposure.
Looking ahead, the company is expected to continue facing financial challenges, with no clear indication of revenue growth in the next fiscal year. The operating cash flow was -$8,603,040 and free cash flow was -$11,095,980, indicating a significant cash outflow. The outlook for the next fiscal year is not provided in the available data, but the current financial performance suggests continued pressure.
The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The low dilution risk is supported by the fact that the number of shares outstanding has not changed between basic and diluted shares, suggesting no imminent dilution from stock options or convertible securities. No recent events such as filings or transcripts are disclosed in the available data.
- Coeptis Therapeutics is experiencing significant financial losses, with a net loss of $11.9 million and an operating loss of $12.9 million.
- The company has a strong current ratio of 4.16, but a negative net cash position after subtracting total debt.
- Return on equity and return on assets are both negative, indicating poor profitability.
- The company's liquidity risk is medium, and dilution risk is low.
- No recent events or segmental data are available to assess strategic or geographic exposure.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- Coeptis Therapeutics Holdings Inc Market data — financials · 2026-05-27